Clearmind Medicine Inc.
About Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $4.1M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.1M
- Shares outstanding
- 1.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 10, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 99% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Clearmind Medicine Inc..
Write a review
News about Clearmind Medicine Inc.
News & sentiment via Polygon.io
